electroCore Expands Intellectual Property Portfolio
February 06 2024 - 7:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced the United States
Patent and Trademark Office has issued a patent related to systems
and methods for treating disorders associated with viruses in the
Coronaviridae family (COVID).
U.S. Patent No. 11,894,148 entitled “Systems and Methods for
Treating Patients With Diseases Associated With Viruses” generally
relates to methods for treating disorders with viruses in the COVID
family using electrical impulses transcutaneously to the vagus
nerve for about 30 seconds to about 5 minutes, from 2 to 5 times
per day, to reduce a level of C-reactive protein in the blood of
the patient.
About electroCore,
Inc.electroCore, Inc. is a commercial stage bioelectronic
medicine and wellness company dedicated to improving health through
its non-invasive vagus nerve stimulation (“nVNS”) technology
platform. Our focus is the commercialization of medical devices for
the management and treatment of certain medical conditions and
consumer product offerings utilizing nVNS to promote general
wellbeing and human performance in the United States and select
overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans; its pipeline or potential markets for
its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the issuance of U.S. and
international patents providing expanded IP coverage; the
possibility of future business models, the potential of nVNS
generally and gammaCore in particular and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to obtain
additional financing necessary to continue electroCore's business,
sales and marketing and product development plans, the
uncertainties inherent in the development of new products or
technologies, the ability to successfully commercialize gammaCore™,
competition in the industry in which electroCore operates and
general market conditions. All forward-looking statements are made
as of the date of this press release, and electroCore undertakes no
obligation to update forward-looking statements or to update the
reasons why actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should refer to all information set forth in this document and
should also refer to the disclosure of risk factors set forth in
the reports and other documents electroCore files with the SEC,
available at www.sec.gov.Contact:ECOR Investor
Relations(973) 302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Sep 2023 to Sep 2024